静脉注射托烷司琼治疗纤维肌痛的疗效和耐受性。
Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
作者信息
Späth M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger C C, Haus U, Färber L, Pongratz D, Müller W
机构信息
Friedrich-Baur-Institute, University of Munich, D-80336 München, Germany.
出版信息
Scand J Rheumatol. 2004;33(4):267-70. doi: 10.1080/03009740410005818.
OBJECTIVE
To determine the efficacy of a serotonin receptor (5-HT(3)) antagonist in the treatment of fibromyalgia (FM) in a prospective, randomized, double-blind, placebo-controlled, multicentre trial.
METHODS
Twenty-one female patients (age 21-63 years) with FM according to the American College of Rheumatology classification criteria for FM were assigned randomly to either a placebo group or to receive a daily intravenous bolus injection of 5 mg tropisetron for 5 days.
RESULTS
In patients receiving tropisetron, the visual analogue scale (VAS) score for pain decreased by 28.9 compared with a decrease of 6.8 in the placebo group [probability (p)=0.063; effect size: 0.794]. Similar results were obtained using a body diagram pain score as a secondary efficacy parameter: mean pain reduction was 27.2 in the tropisetron group, versus 2.8 in the placebo group (p=0.038; effect size: 0.902).
CONCLUSION
5-HT(3) receptor antagonists provide significant pain relief for a group of FM patients.
目的
在一项前瞻性、随机、双盲、安慰剂对照、多中心试验中，确定一种血清素受体（5-HT(3)）拮抗剂治疗纤维肌痛（FM）的疗效。
方法
根据美国风湿病学会纤维肌痛分类标准，21名年龄在21至63岁之间的女性纤维肌痛患者被随机分为安慰剂组或接受每日静脉推注5毫克托烷司琼，持续5天。
结果
接受托烷司琼治疗的患者中，疼痛视觉模拟量表（VAS）评分下降了28.9，而安慰剂组下降了6.8[概率（p）=0.063；效应量：0.794]。使用身体疼痛评分图作为次要疗效参数也得到了类似结果：托烷司琼组平均疼痛减轻27.2，而安慰剂组为2.8（p=0.038；效应量：0.902）。
结论
5-HT(3)受体拮抗剂为一组纤维肌痛患者提供了显著的疼痛缓解。
Zotero 插件